Key facts
- This page summarizes Gwenn Hansen's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
- 10 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2026, 19:42.
Gwenn Hansen - 30 Oct 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- NRIX
- Reported as of
- 30 Oct 2026
- Net transaction value
- -$142,900
- SEC form
- 4
- Accepted by SEC
- 02 Nov 2026, 19:42:20 UTC
- Prior SEC filing
- 15 Oct 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Gwenn Hansen filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 02 Nov 2026.
Change
- Previous filing in this sequence was filed on 15 Oct 2026.
- Current net transaction value: -$142,900.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001817160
Primary reporting owner
Hansen Gwenn
- Relationship
- Chief Scientific Officer
- Address
- C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
- Signature
- /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
- Signature date
- 02 Nov 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRIX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,750
- Change %
- +3.2%
- Price
- $0.000000*
- Shares after
- 120,977
- Date
- 30 Oct 2026
- Ownership
- Direct
NRIX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,859
- Change %
- +2.4%
- Price
- $0.000000*
- Shares after
- 123,836
- Date
- 30 Oct 2026
- Ownership
- Direct
NRIX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,573
- Change %
- +2.9%
- Price
- $0.000000*
- Shares after
- 127,409
- Date
- 30 Oct 2026
- Ownership
- Direct
NRIX
transaction
Common Stock
Sale
- Transaction value
- -$103,986
- Shares
- -3,957
- Change %
- -3.1%
- Price
- $26.28
- Shares after
- 123,452
- Date
- 30 Oct 2026
- Ownership
- Direct
- Footnotes
- F1, F2
NRIX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,452
- Change %
- +1.2%
- Price
- $1.86*
- Shares after
- 124,904
- Date
- 02 Nov 2026
- Ownership
- Direct
- Footnotes
- F3
NRIX
transaction
Common Stock
Sale
- Transaction value
- -$38,914
- Shares
- -1,452
- Change %
- -1.2%
- Price
- $26.80
- Shares after
- 123,452
- Date
- 02 Nov 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRIX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -3,750
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 7,500
- Date
- 30 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
- Exercise price
- $0.000000
- Footnotes
- F4, F5, F6
NRIX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -2,859
- Change %
- -14%
- Price
- $0.000000*
- Shares after
- 17,150
- Date
- 30 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,859
- Exercise price
- $0.000000
- Footnotes
- F4, F6, F7
NRIX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -3,573
- Change %
- -9.1%
- Price
- $0.000000*
- Shares after
- 35,730
- Date
- 30 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,573
- Exercise price
- $0.000000
- Footnotes
- F4, F6, F8
NRIX
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -1,452
- Change %
- -2.4%
- Price
- $0.000000*
- Shares after
- 57,954
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,452
- Exercise price
- $1.86
- Footnotes
- F3, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Footnote F2
Represents the weighted average sale price. The lowest price at which shares were sold was $26.135 and the highest price at which shares were sold was $26.42. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Footnote F3
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Footnote F4
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F5
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Footnote F6
RSUs do not expire; they either vest or are canceled prior to the vest date.
Footnote F7
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Footnote F8
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Footnote F9
The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.